General Information:

Id: 1,162 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Mus musculus
LIKK mouse: mouse selectively expressing constitutively active IKK-beta in hepatocytes; LISR mouse: mouse selectively expressing the I-kappa-B-alpha superrepressor in liver
article
Reference: Cai D et al.(2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11: 183-190 [PMID: 15685173]

Interaction Information:

Comment Expression of mRNAs encoding IL-6 and IL-1beta, the cytokines most induced in HFD and LIKK models, was reduced in salicylate-treated animals by more than 50%. Expression patterns for other genes that were coordinately upregulated by HFD or NF-kappaB activation (LIKK) were concordantly downregulated by salicylate, including genes encoding receptors (IL-8R and TLR-2) and signaling proteins (SOCS-1, SOCS-2 and SOCS-3). These findings indicate that salicylate improves systemic insulin sensitivity in LIKK mice through IKK-beta-NF-kappaB inhibition in liver but not in muscle.
Formal Description
Interaction-ID: 7716

drug/chemical compound

Sodium salicylate

decreases_expression of

gene/protein

IL6

in liver
Drugbank entries Show/Hide entries for IL6